These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 33982548)

  • 1. Factors related to the onset and recurrence of flares in hidradenitis suppurativa patients treated with adalimumab.
    Caposiena Caro RD; Chiricozzi A; Sechi A; Molinelli E; Venturini M; Candi E; DE Simone C; Peris K; Patrizi A; Offidani A; Calzavara-Pinton P; Bianchi L
    Ital J Dermatol Venerol; 2022 Apr; 157(2):137-141. PubMed ID: 33982548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flares as dynamic predictive factor of response to adalimumab in hidradenitis suppurativa: real-life data.
    Caposiena Caro RD; Chiricozzi A; Sechi A; Molinelli E; Venturini M; Candi E; Malvaso D; Peris K; Patrizi A; Offidani A; Calzavara-Pinton P; Bianchi L
    Ital J Dermatol Venerol; 2022 Jun; 157(3):240-246. PubMed ID: 34159775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab.
    Caposiena Caro RD; Cannizzaro MV; Tartaglia C; Bianchi L
    Clin Exp Dermatol; 2020 Jun; 45(4):438-444. PubMed ID: 31630436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
    Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
    Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
    Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A
    Actas Dermosifiliogr; 2023 Oct; 114(9):755-762. PubMed ID: 37331620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study.
    Marzano AV; Genovese G; Casazza G; Moltrasio C; Dapavo P; Micali G; Sirna R; Gisondi P; Patrizi A; Dini V; Bianchini D; Bianchi L; Fania L; Prignano F; Offidani A; Atzori L; Bettoli V; Cannavò SP; Venturini M; Bongiorno MR; Costanzo A; Fabbrocini G; Peris K
    Br J Dermatol; 2021 Jan; 184(1):133-140. PubMed ID: 32119111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
    Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A
    Actas Dermosifiliogr; 2023 Oct; 114(9):T755-T762. PubMed ID: 37479135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: A real-life experience.
    Esme P; Akoglu G; Dalkıran CD; Caliskan E
    Dermatol Ther; 2022 Nov; 35(11):e15782. PubMed ID: 35996992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa.
    Zouboulis CC; Hansen H; Caposiena Caro RD; Damiani G; Delorme I; Pascual JC; Reguiai Z; Trigoni A; Vilarrasa E; Alfageme Roldán F
    Dermatology; 2020; 236(1):25-30. PubMed ID: 31630144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study.
    Gulliver W; Alavi A; Wiseman MC; Gooderham MJ; Rao J; Alam MS; Papp KA; Desjardins O; Jean C
    J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):2431-2439. PubMed ID: 34378812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported quality of life and objective disease severity assessment.
    Rondags A; van Straalen KR; van Hasselt JR; Janse IC; Ardon CB; Vossen ARJV; Prens EP; van der Zee HH; Horváth B
    Br J Dermatol; 2019 May; 180(5):1214-1220. PubMed ID: 30512186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymecycline vs. clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasonography evaluation.
    Caposiena Caro RD; Molinelli E; Brisigotti V; Offidani A; Bianchi L
    Clin Exp Dermatol; 2021 Jan; 46(1):96-102. PubMed ID: 32683727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascularization and fibrosis are important ultrasonographic tools for assessing response to adalimumab in hidradenitis suppurativa: Prospective study of 32 patients.
    Nazzaro G; Calzari P; Passoni E; Vaienti S; Moltrasio C; Barbareschi M; Muratori S; Veraldi S; Marzano AV
    Dermatol Ther; 2021 Jan; 34(1):e14706. PubMed ID: 33368976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: Clinical and ultrasound observations.
    Caposiena Caro RD; Cannizzaro MV; Botti E; Di Raimondo C; Di Matteo E; Gaziano R; Bianchi L
    J Am Acad Dermatol; 2019 May; 80(5):1314-1321. PubMed ID: 30502416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-cell and complement signature in severe hidradenitis suppurativa that does not respond to adalimumab.
    Hambly R; Gatault S; Smith CM; Iglesias-Martinez LF; Kearns S; Rea H; Marasigan V; Lynam-Loane K; Kirthi S; Hughes R; Fletcher JM; Kolch W; Kirby B
    Br J Dermatol; 2023 Jan; 188(1):52-63. PubMed ID: 36689500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort.
    van Straalen KR; Tzellos T; Alavi A; Benhadou F; Cuenca-Barrales C; Daxhelet M; Daoud M; Efthymiou O; Giamarellos-Bourboulis EJ; Guillem P; Gulliver W; Jemec GBE; Katoulis A; Koenig A; Lazaridou E; Lowes MA; Marzano AV; Matusiak L; Molina-Leyva A; Moltrasio C; Pinter A; Potenza C; Prens EP; Romaní J; Saunte DM; Sayed C; Skroza N; Stergianou D; Szepietowski JC; Trigoni A; Vilarrasa E; Kyrgidis A; Zouboulis CC; van der Zee HH
    Dermatology; 2023; 239(3):362-367. PubMed ID: 36630943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.
    Zouboulis CC; Tzellos T; Kyrgidis A; Jemec GBE; Bechara FG; Giamarellos-Bourboulis EJ; Ingram JR; Kanni T; Karagiannidis I; Martorell A; Matusiak Ł; Pinter A; Prens EP; Presser D; Schneider-Burrus S; von Stebut E; Szepietowski JC; van der Zee HH; Wilden SM; Sabat R;
    Br J Dermatol; 2017 Nov; 177(5):1401-1409. PubMed ID: 28636793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa.
    Aarts P; van Huijstee JC; van der Zee HH; van Straalen KR; Prens EP
    J Eur Acad Dermatol Venereol; 2024 May; 38(5):904-909. PubMed ID: 38112226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seven years-experience of adalimumab therapy for Hidradenitis Suppurativa in a real-life dermatologic setting.
    Odorici G; Pacetti L; Forconi R; Schettini N; Zedde P; Corazza M; Bettoli V
    J Dermatolog Treat; 2022 Jun; 33(4):2063-2067. PubMed ID: 33843413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Staphylococcus aureus Carriage in Hidradenitis Suppurativa: Impact on Response to Adalimumab.
    Stergianou D; Tzanetakou V; Argyropoulou M; Kanni T; Bagos PG; Giamarellos-Bourboulis EJ
    Dermatology; 2021; 237(3):372-377. PubMed ID: 33401280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.